| |
Efficiency & productivity in biologics manufacturing is a longstanding goal, as increasingly complex molecules transform approaches to drug development. Process intensification, with advanced techniques & high productivity platforms, accelerates this pace of innovation. Read white paper. .png)
|
|
Today's Big NewsJul 27, 2023 |
|
Thursday, August 3, 2023 | 11am ET / 8am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now. 
|
|
| By Max Bayer Peter Marks, M.D., Ph.D., says he trusts staff reviewers at the FDA, who do “incredibly great work”—but sometimes decisions about efficacy require a broader view. |
|
|
|
| Philadelphia, PA |  |
|
|
By Fraiser Kansteiner Also known as Mounjaro in its approved type 2 diabetes indication, tirzepatide helped patients across two trials—Surmount-3 and Surmount-4—lose up to 26.6% of their body weight, Lilly said Thursday. |
By Nick Paul Taylor Roche’s gene therapy ambitions have taken another blow. Shortly after writing down the value of one of Spark Therapeutics’ hemophilia A candidates, the Swiss drugmaker has removed a second therapy aimed at the disease from its midphase pipeline. |
By Conor Hale Boston Scientific said it expects this year to shake out to between 10.5% and 11.5% sales growth. |
|
Wednesday, September 6, 2023 | 2:00 PM ET / 11:00 AM PT Attendees will learn about tools for interacting with medical images, guiding readers through labeling workflows, and streamlining adjudication and data standardization. Real-world use cases of how pharma companies are enhancing AI development by optimizing reader workflows will be discussed. Register now. 
|
|
By Zoey Becker As Humira biosimilars continue to swarm the market, AbbVie says the situation is playing out as it had expected—or even slightly better. Still, the company is weathering hefty sales declines. |
By James Waldron Biohaven’s attempts to redefine itself as a post-migraine company are continuing to encounter headaches, with the company expressing “deep disappointment” at the FDA’s refusal to review the brain disorder drug troriluzole. |
By Fraiser Kansteiner While it’s still early days for Qdenga’s launch, Takeda is “encouraged by the positive momentum” it’s seen in markets where the product is now available, the company’s CEO, Christophe Weber, said on a conference call Thursday. He added that the company is “already seeing early signs of higher-than-expected demand.” |
By Andrea Park Know Labs is rapidly whittling down the difference between its noninvasive diabetes sensor and traditional continuous glucose monitors. |
By Eric Sagonowsky Teva has worked hard to wrap up its wide-ranging opioid litigation. But a separate lawsuit from the U.S. government related to alleged kickbacks on Copaxone could prove to be "enterprise-threatening," its lawyers recently wrote. |
By James Waldron Merck & Co.’s next-generation pneumococcal vaccine has secured success in a pair of phase 3 trials, bringing the Big Pharma within touching distance of getting the first pneumococcal conjugate shot specifically designed for adults to market. |
By Andrea Park Labcorp closed out the first half of the year with the spinoff of its clinical development business, which left the nest on June 30 as a standalone, publicly traded CRO dubbed Fortrea. |
By Eric Sagonowsky That didn't take long. About a month and a half after Merck & Co. scored a legal win in the insurance case tied to the 2017 "NotPetya" cyberattack, the case is in appeals—again. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss the state of digital phenotyping, plus the vaccine patent lawsuits, the smallest insulin pump, and the rest of the week's headlines. |
|
|---|
|
|
|
Thursday, August 17, 2023 | 11am ET / 8am PT In this webinar, we will discuss the challenges and opportunities for WGBS in an era of cost-effective sequencing: Optimizing protocols and reagents for consistent and reliable results, establishing community standards to ensure WGBS library quality, and more. Register now.
|
|
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
Research The right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
eBook This eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook Take a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
